August 15, 2016 Pharmacosmos launches new website on novel cryoprotectant Pentaisomaltose®

As a step towards the commercialisation of the novel DMSO-free cryoprotectant Pentaisomaltose® the website has been launched. Pharmacosmos is actively seeking clients, distributors and partners to join in the establishment of Pentaisomaltose® as the new golden standard for cryopreservation of selected cell types for clinical use.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.


Please identify if you are a: